Pretax profit at Regeneron Ireland DAC, the Irish arm of US biotech Regeneron, rose 20% to $4.91bn in 2025, according to accounts filed with the Companies Registration Office, as reported by The Irish Times and the Irish Examiner. Revenue rose 3% to $12.53bn and headcount grew to 2,163, most of them in Limerick.
The accounts also record $5.3bn in dividends paid to the parent group in 2025 and a brief interruption to Limerick bulk manufacturing in early 2026, caused by unplanned facility repairs.
- Profit: pretax profit up 20% to $4.91bn in 2025; profit after tax of $4.19bn.
- Revenue: up 3% from $12.15bn to $12.53bn, which the Irish Examiner puts at 87.6% of Regeneron's 2025 global revenue of $14.3bn.
- Tax: corporation tax charge of $716.6m, of which $120m came from the Pillar Two global minimum tax rules.
- Jobs: headcount rose from 2,082 to 2,163, with 1,956 people in production.
- Limerick: bulk manufacturing was "temporarily interrupted" by facility repairs that began in the first quarter of 2026; production recommenced by June 2026.
What do the Regeneron Ireland accounts show?
Regeneron Ireland DAC is the Irish operating company of Regeneron Pharmaceuticals, the New York biotech behind the eye medicine Eylea (aflibercept) and, with Sanofi, the eczema and asthma medicine Dupixent (dupilumab). Its 2025 accounts show pretax profit up 20% to $4.91bn. After a corporation tax charge of $716.6m, profit after tax was $4.19bn. All figures are in US dollars.
Revenue rose by 3%, from $12.15bn to $12.53bn. The Irish Examiner reports that $8.14bn of this came from collaboration revenues and $4.19bn from intercompany revenues. On that basis, the Irish company accounted for 87.6% of Regeneron's global revenue of $14.3bn in 2025.
The profit figure was reached after non-cash amortisation costs of $676.2m and depreciation of $92.4m. Spending on research and development came to $1.09bn.
| Measure | 2025 (2024 where reported) |
|---|---|
| Revenue | $12.53bn (2024: $12.15bn), up 3% |
| Pretax profit | $4.91bn, up 20% |
| Corporation tax charge | $716.6m, including $120m from Pillar Two |
| Profit after tax | $4.19bn |
| Research and development spend | $1.09bn |
| Dividends paid to parent | $5.3bn in 2025, plus $1.5bn in March 2026 |
| Employees | 2,163 (2024: 2,082) |
| Staff costs | $349.5m, including share-based payments of $64.4m |
| Directors' pay (five directors) | $1.88m (2024: $1.66m) |
| Shareholder funds | $6.19bn, including accumulated profits of $1.9bn |
How much corporation tax did Regeneron Ireland pay?
The corporation tax charge for 2025 was $716.6m. The accounts state that the Pillar Two reforms added $120m to the company's Irish corporation tax. Pillar Two is the OECD-agreed global minimum tax of 15% for large multinational groups. The extra $120m is the cost of those rules to the Irish company in 2025.
Where did the profits go?
The company paid dividends of $5.3bn in 2025 to its parent, Regeneron International Holdings LLC. A further dividend of $1.5bn followed in March 2026. Even after these payments, shareholder funds stood at $6.19bn at the end of 2025, including accumulated profits of $1.9bn.
What happened at the Limerick plant in 2026?
The accounts say bulk manufacturing in Limerick "was temporarily interrupted due to unanticipated facility repairs that commenced during the first quarter of 2026". Both newspapers report that production had recommenced by June 2026.
Regeneron's third-quarter 2026 results release, published on 30 October 2026, does not mention Limerick by name. It does list "temporary manufacturing interruption-related costs" of $161.3m in cost of goods sold and $14.8m in cost of collaboration manufacturing for the first nine months of 2026, with no such costs recorded in the third quarter itself. The release does not say which facility they relate to.
How many people does Regeneron employ in Ireland?
Headcount at Regeneron Ireland DAC rose from 2,082 to 2,163 during 2025. Of these, 1,956 worked in production, 75 in research and development, 118 in administration and 14 in commercial roles. Staff costs were $349.5m, including share-based payments of $64.4m. Pay for the five directors rose from $1.66m to $1.88m. Most staff are based at the Limerick plant, with the rest in Dublin.
The Limerick campus sits at Raheen, on the site of the former Dell computer factory. Regeneron first announced the project in December 2013, with a plan for $300m of investment and 300 jobs. In October 2015 it added $350m and 200 jobs, taking planned investment to $650m by the end of 2017, according to the Department of Enterprise. In August 2020 RTÉ reported 400 more jobs at Raheen, which it described as the largest bulk biologics production facility in the country, and said Regeneron had invested more than $1bn in the campus by then. You can follow the company on our Regeneron Ireland page.
Frequently asked questions
What is Regeneron Ireland DAC?
It is the Irish subsidiary of Regeneron Pharmaceuticals. It runs the company's large biologics manufacturing campus in Raheen, Limerick, and has staff in Dublin.
How much profit did Regeneron Ireland make in 2025?
Pretax profit was $4.91bn, up 20%. After a tax charge of $716.6m, profit after tax was $4.19bn.
Why was Limerick production interrupted?
The accounts cite "unanticipated facility repairs" that began in the first quarter of 2026. Production had restarted by June 2026.
What medicines is Regeneron known for?
Its best-known products include Eylea and Eylea HD (aflibercept) for eye disease and Dupixent (dupilumab), developed with Sanofi.
Outlook
The Irish company now carries most of Regeneron's global revenue, so the Limerick plant matters to the whole group. The next set of Irish accounts, covering 2026, should show how far the repair work affected output and costs at Limerick. Regeneron has not said publicly which site the interruption costs in its quarterly release relate to. Priya Life Science will report on any new investment or jobs announcement for the Raheen campus.
Sources
- The Irish Times, Profits jump 20% at Irish arm of US biotech Regeneron, Gordon Deegan, 18 November 2026, accessed 19 November 2026
- Irish Examiner, Profits rise 20% at Irish arm of Regeneron, Gordon Deegan, 18 November 2026, accessed 19 November 2026
- Regeneron Pharmaceuticals, Third quarter 2026 results release, Exhibit 99.1 to SEC filing, 30 October 2026, accessed 19 November 2026
- Department of Enterprise, Tourism and Employment, Department news release on Regeneron Limerick investment, 19 October 2015, accessed 19 November 2026
- RTÉ News, Report on 400 new Regeneron jobs in Limerick, 27 August 2020, accessed 19 November 2026
Cover image: AI-generated illustration. It is not a photograph of Regeneron's Limerick site.